INDIVINA tablett Eesti - eesti - Ravimiamet

indivina tablett

orion corporation - medroksüprogesteroon+östradiool - tablett - 2,5mg+1mg 84tk

INDIVINA tablett Eesti - eesti - Ravimiamet

indivina tablett

orion corporation - medroksüprogesteroon+östradiool - tablett - 5mg+2mg 84tk

Suboxone Euroopa Liit - eesti - EMA (European Medicines Agency)

suboxone

indivior europe limited - buprenorfiini, naloksooni - opioidiga seotud häired - muud närvisüsteemi ravimid - opioidide-sõltuvuse asendusravi meditsiinilise, sotsiaalse ja psühholoogilise ravi raamistikus. naloksooni komponendi eesmärk on ära hoida intravenoosset väärkasutamist. ravi on ette nähtud kasutamiseks täiskasvanutel ja üle 15-aastastel noorukitel, kes on nõustunud sõltuvuse raviks.

Ervebo Euroopa Liit - eesti - EMA (European Medicines Agency)

ervebo

merck sharp & dohme b.v.  - rekombinantse vesikulaarset stomatiiti viirus (tüvi, indiana), mille kustutamise ümbrik glükoproteiini asendada zaire ebolavirus (tüvi kikwit 1995) pinna glükoproteiin - hemorraagiline palavik, ebola - vaktsiinid - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. kasutada ervebo peab olema kooskõlas ametlike soovitustega.

Comirnaty Euroopa Liit - eesti - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Apexxnar Euroopa Liit - eesti - EMA (European Medicines Agency)

apexxnar

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneumokoki infektsioonid - vaktsiinid - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. vt lõigud 4. 4 ja 5. 1, mis käsitleb kaitset spetsiifiliste pneumokokkide serotüüpide eest. apexxnar should be used in accordance with official recommendations. .

Incurin Euroopa Liit - eesti - EMA (European Medicines Agency)

incurin

intervet international bv - estriool - suguhormoonid ja suguhaiguste modulaatorid - koerad - hormoonsõltuva kusepidamatushaiguse ravi, mis on tingitud sphincteri mehhanismi ebakompetentsusest ovariohüstectoriseeritud koertel.

Solensia Euroopa Liit - eesti - EMA (European Medicines Agency)

solensia

zoetis belgium sa - frunevetmab - valuvaigistid - kassid - for the alleviation of pain associated with osteoarthritis in cats.

TETMODIS tablett Eesti - eesti - Ravimiamet

tetmodis tablett

aop orphan pharmaceuticals gmbh - tetrabenasiin - tablett - 25mg 112tk

LARTOKAZ 150 MG/12,5 MG tablett Eesti - eesti - Ravimiamet

lartokaz 150 mg/12,5 mg tablett

laboratorios liconsa s.a. - irbesartaan+hüdroklorotiasiid - tablett - 150mg+12,5mg 98tk; 150mg+12,5mg 56tk; 150mg+12,5mg 28tk; 150mg+12,5mg 14tk